Earnings summaries and quarterly performance for Acumen Pharmaceuticals.
Executive leadership at Acumen Pharmaceuticals.
Daniel O’Connell
Detailed
Chief Executive Officer
CEO
AS
Amy Schacterle
Detailed
Chief Regulatory Officer, Head of Quality
DM
Derek Meisner
Detailed
Chief Legal Officer
ES
Eric Siemers
Detailed
Chief Medical Officer
JD
Jim Doherty
Detailed
President and Chief Development Officer
MZ
Matthew Zuga
Detailed
Chief Financial Officer and Chief Business Officer
RB
Russell Barton
Detailed
Chief Operating Officer
Board of directors at Acumen Pharmaceuticals.
Research analysts who have asked questions during Acumen Pharmaceuticals earnings calls.
Thomas Shrader
BTIG
3 questions for ABOS
Also covers: ALEC, ARCT, CMPS +8 more
Jason Zemansky
Bank of America
2 questions for ABOS
Also covers: BBIO, CYTK, ESPR +5 more
PS
Pete Stavropoulos
Cantor Fitzgerald
2 questions for ABOS
Also covers: ALEC, ARCT, AXSM +7 more
TL
Ting Liu
UBS Group
2 questions for ABOS
Also covers: ALXO
Ananda Ghosh
H.C. Wainwright & Co.
1 question for ABOS
Also covers: ALEC, AMLX, PEPG +1 more
CB
Cameron Bozdog
Bank of America
1 question for ABOS
Also covers: CYTK
JM
Jeff Meacham
Citigroup Inc.
1 question for ABOS
Also covers: LLY, NVAX, PFE
Mark Hitrik
Stifel
1 question for ABOS
PM
Paul Matisse
Stifel Financial Corp.
1 question for ABOS
Also covers: ALKS
Paul Matteis
Stifel
1 question for ABOS
Also covers: ACAD, ALKS, ALNY +11 more
SM
Sarah Madras
Cantor Fitzgerald
1 question for ABOS
Tom Shrader
BTIG
1 question for ABOS
Also covers: ALDX, ALEC, ESPR +4 more
TH
Trung Huynh
UBS Group AG
1 question for ABOS
Also covers: ABBV, AMGN, BMY +5 more
Recent press releases and 8-K filings for ABOS.
Acumen Pharmaceuticals Provides Corporate Update and Project Timelines
ABOS
New Projects/Investments
Guidance Update
- Acumen Pharmaceuticals reported $136 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with an expected cash runway into early 2027.
- The company anticipates topline results in late 2026 for its fully enrolled Phase 2 ALTITUDE-AD study of sabirnetug (ACU193), a monoclonal antibody for early Alzheimer's Disease.
- Pre-clinical candidate data for the Enhanced Brain Delivery (EBD™) program, which aims to develop next-generation oligomer-targeted antibodies, is expected in early 2026.
Jan 12, 2026, 1:33 PM
Acumen Pharmaceuticals Reports Q3 2025 Financials and Provides Clinical Trial Updates
ABOS
Earnings
Guidance Update
Board Change
- Acumen Pharmaceuticals reported $136.1 million in cash and marketable securities as of September 30, 2025, which is expected to support current clinical and operational activities into early 2027.
- For the third quarter of 2025, the company recorded R&D expenses of $22 million, G&A expenses of $4.5 million, and a net loss from operations of $26.5 million.
- The Phase 2 ALTITUDE-AD trial for sabirnetug is progressing, with enrollment completed in March 2025, and top-line results are anticipated in late 2026.
- The Enhanced Brain Delivery (EBD) program is advancing, with a non-clinical data package, including a non-human primate study, expected in early 2026 to inform the decision to advance up to two development candidates.
- Dr. George Golembeski was added to the board as Chairman, increasing the board size to eight.
Nov 12, 2025, 1:00 PM
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
ABOS
Earnings
Guidance Update
Board Change
- Acumen Pharmaceuticals reported a net loss of $26.5 million for the three-month period ended September 30, 2025, compared to a $29.8 million net loss for the same period in 2024.
- As of September 30, 2025, the company held $136.1 million in cash, cash equivalents, and marketable securities, which is projected to support current clinical and operational activities into early 2027.
- The company anticipates reporting topline results for ALTITUDE-AD, a Phase 2 study investigating sabirnetug for early Alzheimer's disease, in late 2026.
- A decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain Delivery™ product candidate is expected in early 2026.
- George Golumbeski, Ph.D., was appointed as the new Chairman to the Board of Directors in November 2025.
Nov 12, 2025, 12:09 PM
Acumen Pharmaceuticals Provides Update on Alzheimer's Drug Sabirnetug Development
ABOS
New Projects/Investments
Guidance Update
- Acumen Pharmaceuticals is advancing sabirnetug, a monoclonal antibody targeting Aβ oligomers for Alzheimer's disease, with Phase 2 study (Altitude AD) results anticipated late next year (2026).
- A subcutaneous formulation of sabirnetug completed a Phase 1 study earlier this year (2025), and the company is exploring its viability for various doses.
- The company announced a collaboration with JCR to combine JCR's transferrin-directed carrier technology with Acumen's antibodies for enhanced brain delivery, with a preclinical package to inform a development decision early next year (2026).
- Phase 1 data (Intercept AD) for sabirnetug showed a favorable safety profile with five cases of ARIA across 48 patients and demonstrated target engagement and a 20%-25% reduction in amyloid PET signal at high doses.
- Acumen plans to seek a partner for Phase 3 development of sabirnetug, recognizing the scale required for late-stage trials.
Nov 11, 2025, 9:40 PM
Viveo Reports Strong 3Q25 Results with Margin Expansion and Significant DIFAL Reversal
ABOS
Earnings
Legal Proceedings
New Projects/Investments
- Viveo reported a 1.4 percentage point (p.p.) expansion in Gross Margin to 14.7% and a 0.9 p.p. expansion in Adjusted EBITDA Margin to 6.1% in 3Q25 compared to 3Q24, continuing an upward trend for Gross Margin.
- The company recognized a positive impact of R$314.6 million in 3Q25 from the reversal of the 2022 DIFAL provision and gains from 2021 DIFAL lawsuits, which positively impacted 3Q25 net income.
- Viveo generated R$166.9 million in cash during 3Q25, reducing its cash cycle to 55 days, and improved its leverage to 4.17x Net Debt / Adjusted Pro Forma EBITDA, the lowest level since 4Q24.
- The company's 2025 priorities include Working Capital, Quality X Quantity, and Operational Excellence, focusing on efficiency, cash generation, and margin expansion across all business lines.
Nov 11, 2025, 12:00 PM
Acumen Pharmaceuticals Provides Update on Alzheimer's Drug Sabirnetug Development
ABOS
New Projects/Investments
- Acumen Pharmaceuticals is developing sabirnetug, an Aβ oligomer-directed antibody, as a distinct and potentially superior treatment for Alzheimer's disease compared to current options.
- The company's confidence in sabirnetug is supported by Phase 1 INTERCEPT-AD study data (2022-2023), which demonstrated target engagement, a competitive safety profile, and positive biomarker effects, with further evidence sought in the ongoing ALTITUDE-AD study.
- Acumen utilized a pTau217 plasma screening assay in the ALTITUDE-AD study, which significantly improved enrollment speed and efficiency, noting its cost-effectiveness compared to PET scans.
- Future development plans include a subcutaneous formulation of sabirnetug, with a Phase 1 study completed, and a collaboration with JCR Pharmaceuticals for an enhanced brain delivery (EBD) approach, targeting clinical entry for EBD in 2027.
Sep 2, 2025, 8:16 PM
Quarterly earnings call transcripts for Acumen Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more